profit from every $100 of sales.
$0$100
Novavax
$9.98-2.16% today
+34.1% in 1 year
1-year low $6.221-year high $12.82
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay $3.74 for every $1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Novavax sold, what it kept, and what it did with the cash.
Sales went from $1.60 billion in 2022 to $1.12 billion in 2025, with $440 million of profit last year.
SalesProfit
Novavax vs. similar companies
Novavax grows the slowest of these 5 and is the cheapest for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Novavax | 3.7× · Cheap | ||
 Vertex Pharmaceuticals | 35.1× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 22.0× · Fair price | ||
 CSL | 22.1× · Fair price |
AI analysis
An AI analyst reads Novavax's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 1,599 | 556 | 682 | 1,123 | |
| 696 | 213 | 479 | 1,050 | |
| -645 | -567 | -249 | 551 | |
| -605 | -487 | -108 | 492 | |
| -658 | -545 | -187 | 440 | |
| -8.42 | -5.41 | -1.23 | 2.58 | |
| 43.5% | 38.2% | 70.3% | 93.5% | |
| -40.3% | -101.8% | -36.5% | 49.0% | |
| -41.1% | -98.0% | -27.5% | 39.2% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 2,259 | 1,797 | 1,560 | 1,177 |
| Cash | 1,337 | 569 | 530 | 241 |
| Total debt | 550 | 229 | 230 | 249 |
| Total liabilities | 2,893 | 2,514 | 2,184 | 1,304 |
| -634 | -717 | -624 | -128 | |
| 78 | 101 | 152 | 173 | |
| – | – | – | 303.3% | |
| 103.8% | 76.0% | 30.1% | -344.7% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -416 | -714 | -87 | -245 | |
| 93 | 59 | 15 | 6 | |
| -509 | -773 | -102 | -251 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 130 | 85 | 48 | 36 |
Valuation
- 3.7×
- –
- –
- -12.4×
- 1.5×
- –
- 3.4×
- -15.2%
- 26.7%
- 0.0%
Profitability
- 93.5%
- 49.0%
- 39.2%
- -9.6%
- -9.5%
- -80.1%
- 89.7%
- -8.4%
- -9.5%
- 57.9%
Growth
- −11.1%
- –
- −149.4%
- –
- +21.5%
Financial health
- 0.0×
- -2.04
- 28.3%
- -5.6×
- 2.48
- 2.45
- 0.57
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 24%of 958
Top 2%of 888
Top 1%of 600
Bottom 7%of 889
Bottom 6%of 987
What analysts expect
- Average price target
- $18.00
- Range
- $11.00 – $25.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 6, 2026 | -0.06 | -0.25 | +76.0% |
| Feb 26, 2026 | 0.11 | -0.66 | +116.7% |
| Nov 6, 2025 | -0.62 | -1.08 | +42.6% |
| Aug 6, 2025 | 0.62 | -0.07 | +985.7% |
| May 8, 2025 | 2.93 | 0.71 | +312.7% |
| Feb 27, 2025 | -0.51 | -0.75 | +32.0% |
| Nov 12, 2024 | -0.76 | -0.87 | +12.6% |
| Aug 8, 2024 | 0.99 | 1.64 | −39.6% |
News
Dow, S&P 500, Nasdaq Futures Edge Higher After Nasdaq Climbs To Record High: SPCX, USAR, CEG, NVAX Stocks In FocusYahoo Finance · Oct 6, 2026Investors Heavily Search Novavax, Inc. (NVAX): Here is What You Need to KnowYahoo Finance · Sep 15, 2026Novavax (NVDA) Following Updated Nuvaxovid Approval Faces A Wide Fair Value DebateYahoo Finance · Aug 29, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
4/7Passes 4 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
54No pass
Benjamin Graham
76Pass
Philip Fisher
63Pass
Peter Lynch
46No pass
Joel Greenblatt
66Pass
Charlie Munger
64Pass
Terry Smith
55No pass
Questions about Novavax
Is Novavax a good stock to buy?
A strong, very profitable business, and the price looks low. 4 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Novavax AI analysis
What does Novavax do?
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. It is in Biotechnology.
Does Novavax pay a dividend?
No. Novavax does not pay a dividend at the moment.
Is Novavax stock halal?
Questionable. Novavax sits in a grey zone: short-term investments may earn interest; type not reported. How we check
How has Novavax stock done over the past year?
Up 34.1% over the past twelve months, to $9.98. It traded between $6.22 and $12.82 and is 22.2% below its high.
Who are Novavax's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with Novavax's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.